Bramwell V, Calvert R T, Edwards G, Scarffe H, Crowther D
Cancer Chemother Pharmacol. 1979;3(4):253-9. doi: 10.1007/BF00254741.
The disposition of cyclophosphamide and its alkylating metabolites was investigated in a group of myeloma patients with varying degrees of renal function impairment. No correlation between renal function and clearance of cyclophosphamide or its alkylating metabolites was found. No evidence of accumulation of cyclophosphamide or alkylating activity was found in four patients receiving radiolabelled cyclophosphamide. Renal function was found to be related to the reciprocal of the area under curve of alkylating activity, indicating that this area increased as renal function decreased. In view of the large nonrenal component of alkylating activity elimination and the large inter-subject variability, it is recommended that dose of cyclophosphamide is not altered in moderate impairment of renal function.
在一组肾功能损害程度不同的骨髓瘤患者中研究了环磷酰胺及其烷基化代谢产物的处置情况。未发现肾功能与环磷酰胺或其烷基化代谢产物清除率之间存在相关性。在四名接受放射性标记环磷酰胺的患者中，未发现环磷酰胺或烷基化活性蓄积的证据。发现肾功能与烷基化活性曲线下面积的倒数相关，表明该面积随肾功能下降而增加。鉴于烷基化活性消除的非肾成分较大且个体间差异较大，建议在肾功能中度损害时不改变环磷酰胺剂量。
